Skip to main content
SpringerLink
Log in

The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

During the last decade, the serotonergic system has emerged as a key player in the appearance of L-DOPA-induced dyskinesia in animal models of Parkinson’s disease. Clinical investigations, based on imaging and postmortem analyses, suggest that the serotonin neurons are also involved in the etiology of this complication of long-term L-DOPA treatment in parkinsonian patients. These findings have stimulated efforts to develop new therapies using drugs targeting the malfunctioning serotonin neurons. In this review, we summarize the experimental and clinical data obtained so far and discuss the prospects for further development of this therapeutic strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA, Tanganelli S, Ferraro L (2005) Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58(3):193–199

    Article  PubMed  CAS  Google Scholar 

  • Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I (1994) Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res 667(2):295–299

    Article  PubMed  CAS  Google Scholar 

  • Arai R, Karasawa N, Geffard M, Nagatsu I (1995) L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 195(3):195–198

    Article  PubMed  CAS  Google Scholar 

  • Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, Picconi B (2010) Synaptic dysfunction in Parkinson’s disease. Biochem Soc Trans 38(2):493–497

    Article  PubMed  CAS  Google Scholar 

  • Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN (2005) Effects of serotonin 5-HT1A agonist in advanced Parkinson’s disease. Mov Disord 20(8):932–936

    Article  PubMed  Google Scholar 

  • Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdere P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bezard E (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol 132:96–168

    Article  PubMed  CAS  Google Scholar 

  • Beaudoin-Gobert M, Epinat J, Metereau E, Duperrier S, Neumane S, Ballanger B, Lavenne F, Liger F, Tourvielle C, Bonnefoi F, Costes N, Bars DL, Broussolle E, Thobois S, Tremblay L, Sgambato-Faure V (2015) Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate. Brain 138(Pt 9):2632–2647

    Article  PubMed  Google Scholar 

  • Bezard E, Carta M (2015) Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson’s disease? Brain 138(Pt 4):829–830

    Article  PubMed  Google Scholar 

  • Bezard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Bjorklund A, Carta M (2013a) Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia. Neurosci Res 77(4):242–246

    Article  PubMed  CAS  Google Scholar 

  • Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Bjorklund A, Carta M (2013b) Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 28(8):1088–1096

    Article  PubMed  CAS  Google Scholar 

  • Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD (2009) Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J Neurosci Res 87(7):1645–1658

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bishop C, George JA, Buchta W, Goldenberg AA, Mohamed M, Dickinson SO, Eissa S, Eskow Jaunarajs KL (2012) Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. Eur J Neurosci 36(6):2839–2848

    Article  PubMed  PubMed Central  Google Scholar 

  • Carta M, Bezard E (2011) Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience 198:245–251

    Article  PubMed  CAS  Google Scholar 

  • Carta M, Tronci E (2014) Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations. Front Neurol 5:78

    Article  PubMed  PubMed Central  Google Scholar 

  • Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain J Neurol 130(Pt 7):1819–1833

    Article  Google Scholar 

  • Carta AR, Frau L, Pinna A, Morelli M (2010) Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Exp Neurol 224(2):395–402

    Article  PubMed  CAS  Google Scholar 

  • Cenci MA (2002) Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease. Amino Acids 23(1–3):105–109

    Article  PubMed  CAS  Google Scholar 

  • Cenci MA, Konradi C (2010) Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 183:209–233

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Cenci MA, Lee CS, Bjorklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10(8):2694–2706

    Article  PubMed  CAS  Google Scholar 

  • Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell’isola R, Katzman AC, Bishop C (2014) Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology 77:1–8

    Article  PubMed  CAS  Google Scholar 

  • Conti MM, Meadows SM, Melikhov-Sosin M, Lindenbach D, Hallmark J, Werner DF, Bishop C (2016) Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats. Neuropharmacology 110(Pt A):125–134

    Article  PubMed  CAS  Google Scholar 

  • de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain J Neurol 127(Pt 12):2747–2754

    Article  Google Scholar 

  • Dupre KB, Eskow KL, Barnum CJ, Bishop C (2008) Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 55(8):1321–1328

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Dupre KB, Ostock CY, Eskow Jaunarajs KL, Button T, Savage LM, Wolf W, Bishop C (2011) Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol 229(2):288–299

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Dupre KB, Ostock CY, George JA, Eskow Jaunarajs KL, Hueston CM, Bishop C (2013) Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats. ACS Chem Neurosci 4(5):747–760

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Eskow KL, Gupta V, Alam S, Park JY, Bishop C (2007) The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 87(3):306–314

    Article  PubMed  CAS  Google Scholar 

  • Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63(7):610–620

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Fidalgo C, Ko WK, Tronci E, Li Q, Stancampiano R, Chuan Q, Bezard E, Carta M (2015) Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease. Neuroscience 298:389–396

    Article  PubMed  CAS  Google Scholar 

  • Fieblinger T, Cenci MA (2015) Zooming in on the small: the plasticity of striatal dendritic spines in L-DOPA-induced dyskinesia. Mov Disord 30(4):484–493

    Article  PubMed  CAS  Google Scholar 

  • Fieblinger T, Graves SM, Sebel LE, Alcacer C, Plotkin JL, Gertler TS, Chan CS, Heiman M, Greengard P, Cenci MA, Surmeier DJ (2014) Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat Commun 5:5316

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G, Cattabeni F, Di Luca M, Calabresi P (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 26(11):2914–2922

    Article  PubMed  CAS  Google Scholar 

  • Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, Rascol O, Russ H (2007) Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov Disord 22(2):179–186

    Article  PubMed  Google Scholar 

  • Gregoire L, Samadi P, Graham J, Bedard PJ, Bartoszyk GD, Di Paolo T (2009) Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinson Relat Disord 15(6):445–452

    Article  Google Scholar 

  • Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG (2005) Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson’s disease. Neuropharmacology 48(4):503–516

    Article  PubMed  CAS  Google Scholar 

  • Hong JY, Oh JS, Lee I, Sunwoo MK, Ham JH, Lee JE, Sohn YH, Kim JS, Lee PH (2014) Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology 82(18):1597–1604

    Article  PubMed  CAS  Google Scholar 

  • Hurley MJ, Jackson MJ, Smith LA, Rose S, Jenner P (2005) Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. Eur J Neurosci 21(12):3240–3250

    Article  PubMed  CAS  Google Scholar 

  • Jaunarajs KL, Dupre KB, Steiniger A, Klioueva A, Moore A, Kelly C, Bishop C (2009) Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. NeuroReport 20(14):1265–1269

    Article  PubMed  CAS  Google Scholar 

  • Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, Matsunaga M (2002) [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson’s disease]. No to shinkei = Brain Nerve 54(2):133–137

    PubMed  Google Scholar 

  • Kannari K, Shen H, Arai A, Tomiyama M, Baba M (2006) Reuptake of L-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci Lett 402(1–2):62–65

    Article  PubMed  CAS  Google Scholar 

  • Lee JY, Seo S, Lee JS, Kim HJ, Kim YK, Jeon BS (2015) Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease. Neurology 85(10):853–860

    Article  PubMed  CAS  Google Scholar 

  • Lindenbach D, Dupre KB, Eskow Jaunarajs KL, Ostock CY, Goldenberg AA, Bishop C (2013) Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson’s disease. Brain Res 1537:327–339

    Article  PubMed  CAS  Google Scholar 

  • Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA (2010) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 112(6):1465–1476

    Article  PubMed  CAS  Google Scholar 

  • Mazzucchi S, Frosini D, Ripoli A, Nicoletti V, Linsalata G, Bonuccelli U, Ceravolo R (2015) Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson’s disease. Acta Neurol Scand 131(3):191–195

    Article  PubMed  CAS  Google Scholar 

  • Meadows SM, Chambers NE, Conti MM, Bossert SC, Tasber C, Sheena E, Varney M, Newman-Tancredi A, Bishop C (2017) Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of L-DOPA-induced dyskinesia. Exp Neurol 292:168–178

    Article  PubMed  CAS  Google Scholar 

  • Mignon LJ, Wolf WA (2005) 8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson’s disease. NeuroReport 16(7):699–703

    Article  PubMed  CAS  Google Scholar 

  • Mosharov EV, Borgkvist A, Sulzer D (2015) Presynaptic effects of levodopa and their possible role in dyskinesia. Mov Disord 30(1):45–53

    Article  PubMed  CAS  Google Scholar 

  • Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Bjorklund A, Bezard E, Carta M (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131(Pt 12):3380–3394

  • Muñoz A, Carlsson T, Tronci E, Kirik D, Bjorklund A, Carta M (2009) Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol 219(1):298–307

    Article  PubMed  CAS  Google Scholar 

  • Navailles S, De Deurwaerdere P (2012) Imbalanced dopaminergic transmission mediated by serotonergic neurons in L-DOPA-induced Dyskinesia. Parkinson’s Dis 2012:323686

    Google Scholar 

  • Navailles S, Bioulac B, Gross C, De Deurwaerdere P (2010) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson’s disease. Neurobiol Dis 38(1):136–143

    Article  PubMed  CAS  Google Scholar 

  • Navailles S, Bioulac B, Gross C, De Deurwaerdere P (2011) Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson’s disease. Neurobiol Dis 41(2):585–590

    Article  PubMed  CAS  Google Scholar 

  • Navailles S, Lagiere M, Contini A, De Deurwaerdere P (2013) Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain. ACS Chem Neurosci 4(5):680–692

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, Serbanescu A, Deckers F, Russ H (2004) Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 27(2):58–62

    Article  PubMed  CAS  Google Scholar 

  • Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destee A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O, Network NS-PC (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82(4):300–307

    Article  PubMed  CAS  Google Scholar 

  • Ostock CY, Dupre KB, Jaunarajs KL, Walters H, George J, Krolewski D, Walker PD, Bishop C (2011) Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. Neuropharmacology 61(4):753–760

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Pavon N, Martin AB, Mendialdua A, Moratalla R (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiat 59(1):64–74

    Article  PubMed  CAS  Google Scholar 

  • Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6(5):501–506

    Article  PubMed  CAS  Google Scholar 

  • Picconi B, Pisani A, Barone I, Bonsi P, Centonze D, Bernardi G, Calabresi P (2005) Pathological synaptic plasticity in the striatum: implications for Parkinson’s disease. Neurotoxicology 26(5):779–783

    Article  PubMed  CAS  Google Scholar 

  • Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P (2014) Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients. J Clin Investig 124(3):1340–1349

    Article  PubMed  CAS  Google Scholar 

  • Porras G, De Deurwaerdere P, Li Q, Marti M, Morgenstern R, Sohr R, Bezard E, Morari M, Meissner WG (2014) L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Sci Rep 4:3730

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Rascol O, Lozano A, Stern M, Poewe W (2011) Milestones in Parkinson’s disease therapeutics. Mov Disord 26(6):1072–1082

    Article  PubMed  Google Scholar 

  • Roussakis AA, Politis M, Towey D, Piccini P (2016) Serotonin-to-dopamine transporter ratios in Parkinson disease: relevance for dyskinesias. Neurology 86(12):1152–1158

    Article  PubMed  CAS  Google Scholar 

  • Rylander D, Parent M, O’Sullivan S, Dovero S, Lees A, Bezard E, Descarries L, Cenci MA (2010) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 68(5):619–628. https://doi.org/10.1002/ana.22097

  • Santini E, Valjent E, Fisone G (2008) Parkinson’s disease: levodopa-induced dyskinesia and signal transduction. FEBS J 275(7):1392–1399

    Article  PubMed  CAS  Google Scholar 

  • Santini E, Heiman M, Greengard P, Valjent E, Fisone G (2009) Inhibition of mTOR signaling in Parkinson’s disease prevents L-DOPA-induced dyskinesia. Sci Signal 2(80):ra36

    Article  PubMed  Google Scholar 

  • Smith R, Wu K, Hart T, Loane C, Brooks DJ, Bjorklund A, Odin P, Piccini P, Politis M (2015) The role of pallidal serotonergic function in Parkinson’s disease dyskinesias: a positron emission tomography study. Neurobiol Aging 36(4):1736–1742

    Article  PubMed  CAS  Google Scholar 

  • Subramaniam S, Napolitano F, Mealer RG, Kim S, Errico F, Barrow R, Shahani N, Tyagi R, Snyder SH, Usiello A (2011) Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nat Neurosci 15(2):191–193

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Svenningsson P, Rosenblad C, af Edholm Arvidson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Bjorklund A, Widner H (2015) Eltoprazine counteracts L-dopa-induced dyskinesias in Parkinson’s disease: a dose-finding study. Brain 138(Pt 4):963–973. https://doi.org/10.1093/brain/awu409

  • Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. NeuroReport 10(3):631–634

    Article  PubMed  CAS  Google Scholar 

  • Tronci E, Napolitano F, Muñoz A, Fidalgo C, Rossi F, Bjorklund A, Usiello A, Carta M (2017) BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. Exp Neurol 297:73–81

    Article  PubMed  CAS  Google Scholar 

  • Ulusoy A, Sahin G, Kirik D (2010) Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc Natl Acad Sci USA 107(29):13159–13164

    Article  PubMed  Google Scholar 

  • Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiat 62(7):800–810

    Article  PubMed  CAS  Google Scholar 

  • Zhang X, Andren PE, Greengard P, Svenningsson P (2008) Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci USA 105(6):2163–2168

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Bengt Mattsson for preparation of figure. Our work presented in this review has been supported by the Michael J Fox Foundation and the Parkinson’s Disease Foundation. MC has been supported by the Italian Ministry of Education, Universities and Research, Progetto di Ricerca di Interesse Nazionale (PRIN) 2010-AHHP5H. AB is supported by the Swedish Research Council (Grant 04X-3824).

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, Section of Physiology, University of Cagliari, Cittadella Universitaria, SS554, Km 4.5, 09042, Monserrato, Italy

    Manolo Carta

  2. Division of Neurobiology, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, 221 84, Lund, Sweden

    Anders Björklund

Authors
  1. Manolo Carta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anders Björklund
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manolo Carta.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carta, M., Björklund, A. The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective. J Neural Transm 125, 1195–1202 (2018). https://doi.org/10.1007/s00702-018-1865-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-018-1865-5

Keywords

Search

Navigation